BRPI0406987A - Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral - Google Patents
Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebralInfo
- Publication number
- BRPI0406987A BRPI0406987A BR0406987-0A BRPI0406987A BRPI0406987A BR PI0406987 A BRPI0406987 A BR PI0406987A BR PI0406987 A BRPI0406987 A BR PI0406987A BR PI0406987 A BRPI0406987 A BR PI0406987A
- Authority
- BR
- Brazil
- Prior art keywords
- hypertension
- treatment
- prevention
- diseases
- medicament
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 5
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 4
- 206010003119 arrhythmia Diseases 0.000 title abstract 3
- 230000006793 arrhythmia Effects 0.000 title abstract 3
- 208000019622 heart disease Diseases 0.000 title abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 title abstract 2
- 206010018364 Glomerulonephritis Diseases 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 210000004204 blood vessel Anatomy 0.000 title abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title abstract 2
- 201000009925 nephrosclerosis Diseases 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 title 1
- 208000006029 Cardiomegaly Diseases 0.000 title 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 title 1
- 206010042434 Sudden death Diseases 0.000 title 1
- 208000032594 Vascular Remodeling Diseases 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 206010008118 cerebral infarction Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000010125 myocardial infarction Diseases 0.000 title 1
- 230000008692 neointimal formation Effects 0.000 title 1
- 238000013146 percutaneous coronary intervention Methods 0.000 title 1
- 208000037803 restenosis Diseases 0.000 title 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 208000018152 Cerebral disease Diseases 0.000 abstract 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 229950004646 azelnidipine Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229960001199 olmesartan medoxomil Drugs 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"MEDICAMENTO PARA A PREVENçãO E/OU TRATAMENTO DE ARTERIOSCLEROSE, MEDICAMENTOS PARA A INIBIçãO DE PROLIFERAçãO DE CéLULAS DO MúSCULO LISO VASCULAR, DE FORMAçãO DE NEOìNTIMA DOS VASOS SANGuìNEOS E DE REMODELAçãO VASCULAR, MEDICAMENTO PARA A PREVENçãO DE RESTENOSE QUE SEGUE INTERVENçãO CORONáRIA PERCUTâNEA, E, MEDICAMENTOS PARA A PROFILAXIA E/OU TRATAMENTO DE HIPERTENSãO OU DOENçAS CAUSADAS POR HIPERTENSãO, DE DOENçAS CARDìACAS, DE ANGINA DO PEITO, DE INFARTO MIOCáRDICO, DE ARRITMIA, DE MORTE SúBITA, DE INSUFICIêNCIA CARDìACA, DE HIPERTROFIA CARDìACA, DE DOENçAS RENAIS, !D NEFROPATIA DIABéTICA, DE GLOMERULONEFRITE, DE NEFROSCLEROSE, DE DOENçAS CEREBROVASCULARES, DE INFARTO CEREBRAL, E DE HEMORRAGIA CEREBRAL". Um remédio para a prevenção e/ou tratamentos para arteriosclerose, hipertensão, doenças cardíacas, doenças renais, ou doenças cerebrovasculares. Ele compreende os ingredientes seguintes como ingredientes ativos: (A) um antagonista do receptor de angiotensina II selecionado do grupo que consiste do composto representado pela fórmula (I) seguinte, (I) ésteres farmacologicamente aceitáveis deste, e sais farmacologicamente aceitáveis deste (por exemplo, olmesartan medoxomil); e (B) um antagonista de cálcio selecionado do grupo que consiste de compostos de 1,4-diidropiridina e os sais farmacologicamente aceitáveis deste (por exemplo, azelnidipina).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003022990 | 2003-01-31 | ||
| JP2003030830 | 2003-02-07 | ||
| PCT/JP2004/000861 WO2004067003A1 (ja) | 2003-01-31 | 2004-01-29 | 動脈硬化及び高血圧症の予防及び治療のための医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0406987A true BRPI0406987A (pt) | 2006-01-10 |
Family
ID=32828917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0406987-0A BRPI0406987A (pt) | 2003-01-31 | 2004-01-29 | Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20060009502A1 (pt) |
| EP (2) | EP3045174A1 (pt) |
| JP (2) | JP3874419B2 (pt) |
| KR (2) | KR101194453B1 (pt) |
| AU (1) | AU2004208615C1 (pt) |
| BR (1) | BRPI0406987A (pt) |
| CA (1) | CA2514921C (pt) |
| CR (1) | CR7928A (pt) |
| EA (1) | EA009983B1 (pt) |
| EC (1) | ECSP055935A (pt) |
| HR (1) | HRP20050754A2 (pt) |
| IL (1) | IL169719A (pt) |
| IS (1) | IS7985A (pt) |
| ME (1) | ME00479B (pt) |
| MX (1) | MXPA05008142A (pt) |
| NZ (1) | NZ541454A (pt) |
| PL (1) | PL377344A1 (pt) |
| RS (1) | RS20050590A (pt) |
| TW (1) | TWI373335B (pt) |
| WO (1) | WO2004067003A1 (pt) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2388469C1 (ru) * | 2009-03-30 | 2010-05-10 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы на восстановительном этапе у больных артериальной гипертонией после перенесенного нарушения мозгового кровообращения без парезов и параличей |
| RU2388470C1 (ru) * | 2009-04-13 | 2010-05-10 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии и абдоминальном ожирении |
| RU2388471C1 (ru) * | 2009-04-13 | 2010-05-10 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии, дислипидемии и абдоминальном ожирении |
| RU2389489C1 (ru) * | 2009-04-13 | 2010-05-20 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии и дислипидемии |
| RU2390335C1 (ru) * | 2009-03-26 | 2010-05-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при стенокардии i-ii функциональных классов |
| RU2390337C1 (ru) * | 2009-04-01 | 2010-05-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии, дислипидемии, нарушении толерантности к глюкозе и абдоминальном ожирении |
| RU2390338C1 (ru) * | 2009-04-13 | 2010-05-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии, нарушении толерантности к глюкозе и абдоминальном ожирении |
| RU2391082C1 (ru) * | 2009-04-01 | 2010-06-10 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии с метаболическим синдромом |
| RU2392934C1 (ru) * | 2009-03-16 | 2010-06-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии |
| RU2392936C1 (ru) * | 2009-04-06 | 2010-06-27 | Илья Николаевич Медведев | Способ оптимизации функциональной реактивности сердечно-сосудистой системы у больных с артериальной гипертонией и метаболическим синдромом пожилого и старческого возраста |
| RU2393836C1 (ru) * | 2009-04-06 | 2010-07-10 | Илья Николаевич Медведев | Способ оптимизации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии, дислипидемии и абдоминальном ожирении в пожилом и старческом возрасте |
| RU2398559C1 (ru) * | 2009-04-14 | 2010-09-10 | Илья Николаевич Медведев | Способ оптимизации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии в пожилом и старческом возрасте |
| RU2400223C1 (ru) * | 2009-03-30 | 2010-09-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при сочетании артериальной гипертонии со стенокардией i-ii функциональных классов |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006131511A (ja) * | 2004-11-02 | 2006-05-25 | Japan Health Science Foundation | 虚血性脳障害抑制剤 |
| JP5289043B2 (ja) * | 2005-04-12 | 2013-09-11 | ヴィコール・ファルマ・アーベー | 新規な三環系アンジオテンシンｉｉアゴニスト |
| EP1869023B1 (en) * | 2005-04-12 | 2012-01-11 | Vicore Pharma AB | New tricyclic angiotensin ii agonists |
| WO2006123765A1 (ja) * | 2005-05-20 | 2006-11-23 | Daiichi Sankyo Company, Limited | フィルムコーティング製剤 |
| KR101314439B1 (ko) * | 2005-05-20 | 2013-10-07 | 다이이찌 산쿄 가부시키가이샤 | 덱스트로오스 함유 필름 코팅 제제 |
| CN101247832B (zh) * | 2005-06-27 | 2011-12-28 | 第一三共株式会社 | 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂 |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| TW200736245A (en) * | 2005-11-29 | 2007-10-01 | Sankyo Co | Acid addition salts of optically active dihydropyridine derivatives |
| TW200806648A (en) | 2005-11-29 | 2008-02-01 | Sankyo Co | Acid addition salts of dihydropyridine derivatives |
| KR101422052B1 (ko) * | 2006-04-19 | 2014-07-23 | 아지노모토 가부시키가이샤 | 할선 정제 |
| EP1891952B1 (en) * | 2006-05-04 | 2011-10-05 | LEK Pharmaceuticals d.d. | Pharmaceutical composition of olmesartan medoxomil |
| US20100237530A1 (en) * | 2006-06-27 | 2010-09-23 | Daiichi Sankyo Company, Limited | Compressed preparation |
| TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| KR101247583B1 (ko) * | 2006-12-08 | 2013-03-26 | 한미사이언스 주식회사 | 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물 |
| TW200833325A (en) * | 2006-12-26 | 2008-08-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition comprising ascorbic acid |
| TWI414310B (zh) * | 2006-12-26 | 2013-11-11 | Daiichi Sankyo Co Ltd | 溶出性改善之醫藥品組成物 |
| TWI488658B (zh) * | 2006-12-26 | 2015-06-21 | Daiichi Sankyo Co Ltd | 溶出性之改善方法 |
| TWI402083B (zh) * | 2006-12-26 | 2013-07-21 | Daiichi Sankyo Co Ltd | 固形製劑及其安定化方法 |
| JP2008290989A (ja) * | 2007-05-28 | 2008-12-04 | Ube Ind Ltd | ジヒドロピリジン誘導体の酸付加塩を含有する医薬 |
| US8133924B2 (en) * | 2007-08-13 | 2012-03-13 | Rhodia Operations | Demulsifiers and methods for use in pharmaceutical applications |
| US20110038898A1 (en) | 2008-03-13 | 2011-02-17 | Shuichi Yada | Dissolution properties of drug products containing olmesartan medoxomil |
| EA201170913A1 (ru) * | 2008-12-30 | 2012-01-30 | Абды Ибрахым Иладж Санайи Ве Тыджарет Аноным Сыркеты | Фармацевтические составы олмесартана |
| WO2010107081A1 (ja) * | 2009-03-19 | 2010-09-23 | 第一三共株式会社 | 包装により安定保存された固形製剤 |
| IT1400311B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. |
| US20220218647A1 (en) | 2019-05-21 | 2022-07-14 | Societe Des Produits Nestle S.A. | Dietary butyrate |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK161312C (da) | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
| US4573909A (en) * | 1984-08-03 | 1986-03-04 | Granco-Clark, Inc. | Billet heating furnace with adjustable pressurized entrance seal |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| US4772596A (en) | 1986-10-09 | 1988-09-20 | Sankyo Company Limited | Dihydropyridine derivatives, their preparation and their use |
| FR2681067B1 (fr) | 1991-09-10 | 1993-12-17 | Elf Sanofi | Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
| US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
| US5260285A (en) * | 1990-12-07 | 1993-11-09 | Merck & Co., Inc. | Substituted imidazopyridazines as angiotensin II antagonists |
| CA2057089A1 (en) | 1990-12-07 | 1992-06-08 | Eric E. Allen | Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists |
| US5250521A (en) * | 1990-12-07 | 1993-10-05 | Merck & Co., Inc. | Substituted pyrazolopyrimidines as angiotensin II antagonists |
| US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
| WO1992010097A1 (en) | 1990-12-14 | 1992-06-25 | Smithkline Beecham Corporation | Angiotensin ii receptor blocking compositions |
| CA2061607C (en) | 1991-02-21 | 1999-01-19 | Hiroaki Yanagisawa | 1-biphenylimidazole derivatives, their preparation and their therapeutic use |
| US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
| EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
| US5238942A (en) | 1991-05-10 | 1993-08-24 | Merck & Co., Inc. | Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists |
| NZ242724A (en) * | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
| US5492904A (en) * | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| US5246944A (en) | 1991-08-13 | 1993-09-21 | Merck & Co., Inc. | Quinoline angiotensin ii antagonists incorporating a substituted benzyl element |
| CA2079982A1 (en) | 1991-10-07 | 1993-04-08 | Stephen E. De Laszlo | Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists |
| FR2688781B1 (fr) * | 1992-03-23 | 1994-07-01 | Sanofi Elf | Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
| JP2750331B2 (ja) * | 1992-04-23 | 1998-05-13 | 株式会社ジャパンエナジー | エピタキシャル成長用基板およびエピタキシャル成長方法 |
| US5312820A (en) * | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| US5343167A (en) * | 1993-02-03 | 1994-08-30 | Silicon Systems, Inc. | One-shot control circuit for tracking a voltage-controlled oscillator |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| JP3057471B2 (ja) * | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | アンジオテンシンｉｉ介在性諸疾患の予防または治療剤 |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| GB9405833D0 (en) * | 1994-03-24 | 1994-05-11 | Pfizer Ltd | Separation of the enantiomers of amlodipine |
| US6251436B1 (en) * | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| US5952006A (en) * | 1995-09-29 | 1999-09-14 | L.A.M. Pharmaceuticals, Llc | Drug preparations for treating impotency |
| US6036977A (en) * | 1995-09-29 | 2000-03-14 | L.A.M. Pharmaceutical Corp. | Drug preparations for treating sexual dysfunction |
| US5808084A (en) * | 1996-02-14 | 1998-09-15 | Pfizer, Inc. | Process for the preparation of 1,4-dihydropyridinedicarboxylic esters |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
| US6420412B2 (en) * | 1996-03-29 | 2002-07-16 | Smithkline Beecham Corporation | Eprosartan dihydate and a process for its production and formulation |
| JP4316013B2 (ja) | 1996-03-29 | 2009-08-19 | スミスクライン・ビーチャム・コーポレイション | エプロサルタン二水和物ならびにその製法および処方 |
| IL128059A (en) * | 1996-07-15 | 2003-12-10 | Sankyo Co | Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors |
| US5879303A (en) * | 1996-09-27 | 1999-03-09 | Atl Ultrasound | Ultrasonic diagnostic imaging of response frequency differing from transmit frequency |
| WO1999000383A1 (en) | 1997-06-27 | 1999-01-07 | Smithkline Beecham Corporation | Eprosartan monohydrate |
| ES2273433T3 (es) | 1997-08-06 | 2007-05-01 | Smithkline Beecham Corporation | Complejo por neutralizacion de cargas con arginilo de eprosartan y procedimiento para su produccion y formulacion. |
| US6630498B2 (en) * | 1997-08-06 | 2003-10-07 | Smithkline Beecham Corporation | Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation |
| US6558699B2 (en) * | 1997-11-17 | 2003-05-06 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| KR100597922B1 (ko) | 1997-11-17 | 2006-07-10 | 스미스클라인 비참 코포레이션 | 고용량 약물 로딩 속효성 및 변형 방출형 경구 투여용제형 및 그의 제조 방법 |
| US20030022928A1 (en) * | 1998-03-11 | 2003-01-30 | Smithkline Beecham Corporation | Novel compositions of eprosartan |
| ZA991922B (en) | 1998-03-11 | 1999-09-13 | Smithkline Beecham Corp | Novel compositions of eprosartan. |
| DE69927154T2 (de) | 1998-06-25 | 2006-06-29 | Lavipharm Laboratories, Inc. | Vorrichtung und verfahren zur behandlung von erektionsstörungen |
| US20020127254A1 (en) * | 1998-06-25 | 2002-09-12 | Lavipharm Laboratories Inc. | Devices for local and systemic delivery of active substance and methods of manufacturing thereof |
| US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| AU1157500A (en) * | 1998-11-06 | 2000-05-29 | Boehringer Ingelheim International Gmbh | Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof |
| WO2000027397A1 (en) * | 1998-11-06 | 2000-05-18 | Glaxo Group Limited | Antihypertensive medicaments containing lacidipine and telmisartan |
| CA2359747A1 (en) * | 1999-02-09 | 2000-08-17 | Lexicon Genetics Incorporated | Human uncoupling proteins and polynucleotides encoding the same |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| EP1867342A1 (en) * | 1999-07-21 | 2007-12-19 | Takeda Pharmaceutical Company Limited | Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| RS50377B (sr) * | 1999-08-30 | 2009-11-10 | Sanofi-Aventis Deutschland Gmbh., | Inhibitori sistema renin-angiotenzin i njihova primena |
| US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| GB0008332D0 (en) | 2000-04-04 | 2000-05-24 | Pfizer Ltd | Treament |
| EP1272220B2 (en) | 2000-04-10 | 2016-07-27 | Nicholas John Wald | Formulation for the prevention of cardiovascular disease |
| GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| WO2001076598A1 (en) * | 2000-04-11 | 2001-10-18 | Sankyo Company, Limited | Stabilized pharmaceutical compositions containing calcium channel blockers |
| JP4327376B2 (ja) * | 2000-04-11 | 2009-09-09 | 第一三共株式会社 | カルシウムブロッカーを含有する安定化された薬剤組成物 |
| DE10018401A1 (de) | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| EP1314425A4 (en) * | 2000-08-30 | 2004-06-02 | Sankyo Co | MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE |
| SK5992003A3 (en) * | 2000-11-21 | 2003-11-04 | Sankyo Co | Medicinal composition comprising an angiotensin II receptor antagonist and one or more diuretics and use thereof |
| AU2002226365A1 (en) * | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
| US20030138494A1 (en) * | 2001-05-15 | 2003-07-24 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| CA2456034A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
| MXPA04001878A (es) * | 2001-08-28 | 2004-06-15 | Sankyo Co | Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii. |
| US6680334B2 (en) * | 2001-08-28 | 2004-01-20 | Pfizer Inc | Crystalline material |
| EP1438027A1 (en) * | 2001-10-25 | 2004-07-21 | DepoMed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| JP5100039B2 (ja) * | 2003-01-31 | 2012-12-19 | 第一三共株式会社 | 動脈硬化及び高血圧症の予防及び治療のための医薬 |
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| US20050209588A1 (en) * | 2003-09-04 | 2005-09-22 | Crum, Kaminski & Larson, Llc | HIFU resculpturing and remodeling of heart valves |
| US20050209288A1 (en) * | 2004-01-12 | 2005-09-22 | Grogan Donna R | Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| CN101247832B (zh) * | 2005-06-27 | 2011-12-28 | 第一三共株式会社 | 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂 |
-
2004
- 2004-01-29 EP EP15198230.3A patent/EP3045174A1/en not_active Withdrawn
- 2004-01-29 HR HR20050754A patent/HRP20050754A2/hr not_active Application Discontinuation
- 2004-01-29 WO PCT/JP2004/000861 patent/WO2004067003A1/ja not_active Ceased
- 2004-01-29 EA EA200501075A patent/EA009983B1/ru active Protection Beyond IP Right Term
- 2004-01-29 JP JP2005504752A patent/JP3874419B2/ja not_active Expired - Lifetime
- 2004-01-29 MX MXPA05008142A patent/MXPA05008142A/es active IP Right Grant
- 2004-01-29 ME MEP-2008-747A patent/ME00479B/me unknown
- 2004-01-29 AU AU2004208615A patent/AU2004208615C1/en not_active Expired
- 2004-01-29 KR KR1020057013811A patent/KR101194453B1/ko not_active Expired - Fee Related
- 2004-01-29 BR BR0406987-0A patent/BRPI0406987A/pt not_active Application Discontinuation
- 2004-01-29 PL PL377344A patent/PL377344A1/pl unknown
- 2004-01-29 EP EP04706359A patent/EP1604664A4/en not_active Ceased
- 2004-01-29 CA CA2514921A patent/CA2514921C/en not_active Expired - Lifetime
- 2004-01-29 KR KR1020127010244A patent/KR20120058618A/ko not_active Ceased
- 2004-01-29 NZ NZ541454A patent/NZ541454A/en not_active IP Right Cessation
- 2004-01-29 RS YUP-2005/0590A patent/RS20050590A/sr unknown
- 2004-01-30 TW TW093102081A patent/TWI373335B/zh not_active IP Right Cessation
-
2005
- 2005-07-18 IL IL169719A patent/IL169719A/en unknown
- 2005-07-22 US US11/188,275 patent/US20060009502A1/en not_active Abandoned
- 2005-07-28 EC EC2005005935A patent/ECSP055935A/es unknown
- 2005-07-29 CR CR7928A patent/CR7928A/es unknown
- 2005-08-17 IS IS7985A patent/IS7985A/is unknown
-
2006
- 2006-07-11 US US11/484,132 patent/US20060252805A1/en not_active Abandoned
- 2006-07-11 US US11/484,417 patent/US20060252806A1/en not_active Abandoned
-
2008
- 2008-03-06 US US12/074,778 patent/US20080176909A1/en not_active Abandoned
- 2008-03-06 US US12/074,797 patent/US20080214626A1/en not_active Abandoned
- 2008-03-06 US US12/074,779 patent/US20080176910A1/en not_active Abandoned
-
2010
- 2010-04-26 JP JP2010100986A patent/JP5190086B2/ja not_active Expired - Lifetime
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2392934C1 (ru) * | 2009-03-16 | 2010-06-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии |
| RU2390335C1 (ru) * | 2009-03-26 | 2010-05-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при стенокардии i-ii функциональных классов |
| RU2400223C1 (ru) * | 2009-03-30 | 2010-09-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при сочетании артериальной гипертонии со стенокардией i-ii функциональных классов |
| RU2388469C1 (ru) * | 2009-03-30 | 2010-05-10 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы на восстановительном этапе у больных артериальной гипертонией после перенесенного нарушения мозгового кровообращения без парезов и параличей |
| RU2390337C1 (ru) * | 2009-04-01 | 2010-05-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии, дислипидемии, нарушении толерантности к глюкозе и абдоминальном ожирении |
| RU2391082C1 (ru) * | 2009-04-01 | 2010-06-10 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии с метаболическим синдромом |
| RU2393836C1 (ru) * | 2009-04-06 | 2010-07-10 | Илья Николаевич Медведев | Способ оптимизации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии, дислипидемии и абдоминальном ожирении в пожилом и старческом возрасте |
| RU2392936C1 (ru) * | 2009-04-06 | 2010-06-27 | Илья Николаевич Медведев | Способ оптимизации функциональной реактивности сердечно-сосудистой системы у больных с артериальной гипертонией и метаболическим синдромом пожилого и старческого возраста |
| RU2389489C1 (ru) * | 2009-04-13 | 2010-05-20 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии и дислипидемии |
| RU2390338C1 (ru) * | 2009-04-13 | 2010-05-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии, нарушении толерантности к глюкозе и абдоминальном ожирении |
| RU2388471C1 (ru) * | 2009-04-13 | 2010-05-10 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии, дислипидемии и абдоминальном ожирении |
| RU2388470C1 (ru) * | 2009-04-13 | 2010-05-10 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии и абдоминальном ожирении |
| RU2398559C1 (ru) * | 2009-04-14 | 2010-09-10 | Илья Николаевич Медведев | Способ оптимизации функциональной реактивности сердечно-сосудистой системы при артериальной гипертонии в пожилом и старческом возрасте |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0406987A (pt) | Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral | |
| KR102475124B1 (ko) | sGC 자극제를 사용한 CNS 질환의 치료 | |
| US20150352107A1 (en) | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions | |
| BRPI0510414A (pt) | uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos | |
| JP2014526492A5 (pt) | ||
| NZ530630A (en) | Combination therapy comprising atorvastatin and an alpha-andregeneric receptor blocker | |
| BR0312940A (pt) | Inibidores de quinases | |
| GEP20105004B (en) | Substituted benzimidazoles as kinase inhibitors | |
| JP5968927B2 (ja) | 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用 | |
| AU2017216429A1 (en) | Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH) | |
| CA2920811A1 (en) | Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir | |
| NO20032261L (no) | Medisinske preparater | |
| JPH10511080A (ja) | 哺乳類細胞の増殖を治療するためのハロゲン化芳香族の使用 | |
| EP3132803A2 (en) | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | |
| EP2787993B1 (en) | TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR | |
| WO2017054787A1 (en) | Pharmaceutical composition comprising the combination of candesartan, amlodipine and hydrochlorothiazide | |
| McKenney et al. | Safety of extended-release niacin/laropiprant in patients with dyslipidemia | |
| CN106164059A (zh) | 用天冬酰胺内肽酶（aep）抑制剂以及相关组合物对神经退行性疾病的治疗 | |
| NO20065551L (no) | Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin | |
| ES2847904T3 (es) | Medicamento para la prevención o el tratamiento de la hipertensión | |
| AU2008334932B2 (en) | Method and composition for treating an alpha adrenoceptor-mediated condition | |
| Poulsen et al. | Major drug interactions | |
| JP2015051991A (ja) | セロトニン受容体介在状態を治療する方法及び組成物 | |
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| EP2680838A1 (en) | TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |